

# Non-alcoholic Steatohepatitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

<https://marketpublishers.com/r/N65FC5A11CFFEN.html>

Date: April 2025

Pages: 104

Price: US\$ 3,200.00 (Single User License)

ID: N65FC5A11CFFEN

## Abstracts

### Non-alcoholic Steatohepatitis Drug Market Summary

#### Introduction

Non-alcoholic Steatohepatitis (NASH) is a severe form of non-alcoholic fatty liver disease marked by liver inflammation and fibrosis, often linked to obesity and metabolic syndrome. Globally, NASH prevalence rose from 264 million in 2018 to 296 million in 2023, projected to reach 342 million by 2030. The NASH Drug market focuses on therapies to halt progression, reduce fat accumulation, and prevent cirrhosis, with resmetirom—approved by the FDA in March 2024 by Madrigal Pharmaceuticals—as the first drug for moderate-to-advanced NASH fibrosis. The industry is characterized by intense R&D, addressing a growing epidemic with significant unmet needs and a shift toward metabolic-targeted therapies.

#### Market Size and Growth Forecast

The global Non-alcoholic Steatohepatitis Drug market is estimated at USD 0.3 billion to USD 0.6 billion in 2025, with an extraordinary CAGR of 100% to 110% through 2030, potentially reaching USD 10 billion to USD 24 billion. This explosive growth reflects resmetirom's approval and robust pipeline activity.

#### Regional Analysis

North America: Expected at 95% to 105%, the U.S. leads with high obesity rates and advanced healthcare. Trends focus on metabolic drugs and diagnostics.

Europe: Forecasted at 90% to 100%, Germany and France grow rapidly. Trends emphasize lifestyle-linked therapies.

Asia Pacific: Projected at 100% to 110%, China drives growth with rising prevalence. Trends highlight local R&D.

South America: Anticipated at 85% to 95%, Brazil emerges. Trends favor affordable options.

Middle East and Africa: Expected at 80% to 90%, UAE leads. Trends focus on awareness and access.

### Key Market Players

AstraZeneca PLC: A UK leader, AstraZeneca targets metabolic diseases like NASH.

Eli Lilly: A U.S. firm, Lilly advances NASH therapies with metabolic focus.

Gilead Sciences: A U.S. giant, Gilead explores liver disease solutions.

Merck & Co. Inc.: A U.S. player, Merck innovates in NASH treatments.

Novo Nordisk: A Danish company, Novo Nordisk leverages diabetes expertise for NASH.

Novartis AG: A Swiss firm, Novartis focuses on fibrosis therapies.

Pfizer Inc.: A U.S. leader, Pfizer targets metabolic liver conditions.

Roche Holding AG: A Swiss giant, Roche explores NASH innovations.

Enanta Pharmaceuticals Inc.: A U.S. biotech, Enanta develops liver-targeted drugs.

Ionis Pharmaceuticals Inc.: A U.S. entity, Ionis advances RNA therapies for NASH.

NGM Biopharmaceuticals Inc.: A U.S. firm, NGM targets metabolic pathways.

Pliant Therapeutics Inc.: A U.S. biotech, Pliant focuses on anti-fibrotic agents.

Terns Pharmaceuticals Inc.: A U.S. company, Terns innovates in NASH treatments.

89bio Inc.: A U.S. entity, 89bio develops metabolic therapies.

### Porter's Five Forces Analysis

Threat of New Entrants: High, with blockbuster potential attracting biotechs despite R&D costs.

Threat of Substitutes: Moderate, with lifestyle interventions competing, but drugs offer scalability.

Bargaining Power of Buyers: Moderate, as unmet needs limit options, though insurers push pricing.

Bargaining Power of Suppliers: Low-to-moderate, with broad supply chains supporting drug production.

Competitive Rivalry: Intense, driven by first-mover advantages and pipeline races among Gilead and Merck.

### Market Opportunities and Challenges

#### Opportunities

Rising Prevalence: 342 million cases by 2030 create vast demand for NASH drugs.

First Approval: Resmetirom's success sets a precedent, accelerating market entry.

Metabolic Focus: Overlap with obesity and diabetes opens cross-therapeutic potential.

Investment Surge: High growth rates attract significant R&D funding.

## Challenges

**Diagnostic Barriers:** NASH's silent progression delays treatment, limiting market reach.

**High Costs:** Expensive drugs like resmetirom challenge affordability in emerging markets.

**Regulatory Hurdles:** Rigorous efficacy proof slows pipeline approvals.

**Competition:** Crowded pipeline increases rivalry, risking market saturation.

## Contents

### **CHAPTER 1 EXECUTIVE SUMMARY**

### **CHAPTER 2 ABBREVIATION AND ACRONYMS**

### **CHAPTER 3 PREFACE**

- 3.1 Research Scope
- 3.2 Research Sources
  - 3.2.1 Data Sources
  - 3.2.2 Assumptions
- 3.3 Research Method
- Chapter Four Market Landscape
- 4.1 Market Overview
- 4.2 Classification/Types
- 4.3 Application/End Users

### **CHAPTER 5 MARKET TREND ANALYSIS**

- 5.1 Introduction
- 5.2 Drivers
- 5.3 Restraints
- 5.4 Opportunities
- 5.5 Threats

### **CHAPTER 6 INDUSTRY CHAIN ANALYSIS**

- 6.1 Upstream/Suppliers Analysis
- 6.2 Non-Alcoholic Steatohepatitis Drug Analysis
  - 6.2.1 Technology Analysis
  - 6.2.2 Cost Analysis
  - 6.2.3 Market Channel Analysis
- 6.3 Downstream Buyers/End Users

### **CHAPTER 7 LATEST MARKET DYNAMICS**

- 7.1 Latest News
- 7.2 Merger and Acquisition

7.3 Planned/Future Project

7.4 Policy Dynamics

## **CHAPTER 8 HISTORICAL AND FORECAST NON-ALCOHOLIC STEATOHEPATITIS DRUG MARKET IN NORTH AMERICA (2020-2030)**

8.1 Non-Alcoholic Steatohepatitis Drug Market Size

8.2 Non-Alcoholic Steatohepatitis Drug Market by End Use

8.3 Competition by Players/Suppliers

8.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type

8.5 Key Countries Analysis

8.5.1 United States

8.5.2 Canada

8.5.3 Mexico

## **CHAPTER 9 HISTORICAL AND FORECAST NON-ALCOHOLIC STEATOHEPATITIS DRUG MARKET IN SOUTH AMERICA (2020-2030)**

9.1 Non-Alcoholic Steatohepatitis Drug Market Size

9.2 Non-Alcoholic Steatohepatitis Drug Market by End Use

9.3 Competition by Players/Suppliers

9.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type

9.5 Key Countries Analysis

9.5.1 Brazil

9.5.2 Argentina

9.5.3 Chile

9.5.4 Peru

## **CHAPTER 10 HISTORICAL AND FORECAST NON-ALCOHOLIC STEATOHEPATITIS DRUG MARKET IN ASIA & PACIFIC (2020-2030)**

10.1 Non-Alcoholic Steatohepatitis Drug Market Size

10.2 Non-Alcoholic Steatohepatitis Drug Market by End Use

10.3 Competition by Players/Suppliers

10.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type

10.5 Key Countries Analysis

10.5.1 China

10.5.2 India

10.5.3 Japan

- 10.5.4 South Korea
- 10.5.5 Southeast Asia
- 10.5.6 Australia

## **CHAPTER 11 HISTORICAL AND FORECAST NON-ALCOHOLIC STEATOHEPATITIS DRUG MARKET IN EUROPE (2020-2030)**

- 11.1 Non-Alcoholic Steatohepatitis Drug Market Size
- 11.2 Non-Alcoholic Steatohepatitis Drug Market by End Use
- 11.3 Competition by Players/Suppliers
- 11.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type
- 11.5 Key Countries Analysis
  - 11.5.1 Germany
  - 11.5.2 France
  - 11.5.3 United Kingdom
  - 11.5.4 Italy
  - 11.5.5 Spain
  - 11.5.6 Belgium
  - 11.5.7 Netherlands
  - 11.5.8 Austria
  - 11.5.9 Poland
  - 11.5.10 Russia

## **CHAPTER 12 HISTORICAL AND FORECAST NON-ALCOHOLIC STEATOHEPATITIS DRUG MARKET IN MEA (2020-2030)**

- 12.1 Non-Alcoholic Steatohepatitis Drug Market Size
- 12.2 Non-Alcoholic Steatohepatitis Drug Market by End Use
- 12.3 Competition by Players/Suppliers
- 12.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type
- 12.5 Key Countries Analysis
  - 12.5.1 Egypt
  - 12.5.2 Israel
  - 12.5.3 South Africa
  - 12.5.4 Gulf Cooperation Council Countries
  - 12.5.5 Turkey

## **CHAPTER 13 SUMMARY FOR GLOBAL NON-ALCOHOLIC STEATOHEPATITIS DRUG MARKET (2020-2025)**

- 13.1 Non-Alcoholic Steatohepatitis Drug Market Size
- 13.2 Non-Alcoholic Steatohepatitis Drug Market by End Use
- 13.3 Competition by Players/Suppliers
- 13.4 Non-Alcoholic Steatohepatitis Drug Market Size by Type

## **CHAPTER 14 GLOBAL NON-ALCOHOLIC STEATOHEPATITIS DRUG MARKET FORECAST (2025-2030)**

- 14.1 Non-Alcoholic Steatohepatitis Drug Market Size Forecast
- 14.2 Non-Alcoholic Steatohepatitis Drug Application Forecast
- 14.3 Competition by Players/Suppliers
- 14.4 Non-Alcoholic Steatohepatitis Drug Type Forecast

## **CHAPTER 15 ANALYSIS OF GLOBAL KEY VENDORS**

### **15.1 AstraZeneca PLC**

- 15.1.1 Company Profile
- 15.1.2 Main Business and Non-alcoholic Steatohepatitis Drug Information
- 15.1.3 SWOT Analysis of AstraZeneca PLC
- 15.1.4 AstraZeneca PLC Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

### **15.2 Eli Lilly**

- 15.2.1 Company Profile
- 15.2.2 Main Business and Non-alcoholic Steatohepatitis Drug Information
- 15.2.3 SWOT Analysis of Eli Lilly
- 15.2.4 Eli Lilly Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

### **15.3 Gilead Sciences**

- 15.3.1 Company Profile
- 15.3.2 Main Business and Non-alcoholic Steatohepatitis Drug Information
- 15.3.3 SWOT Analysis of Gilead Sciences
- 15.3.4 Gilead Sciences Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

### **15.4 Merck & Co. Inc.**

- 15.4.1 Company Profile
- 15.4.2 Main Business and Non-alcoholic Steatohepatitis Drug Information
- 15.4.3 SWOT Analysis of Merck & Co. Inc.
- 15.4.4 Merck & Co. Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin



and Market Share (2020-2025)

#### 15.5 Novo Nordisk

15.5.1 Company Profile

15.5.2 Main Business and Non-alcoholic Steatohepatitis Drug Information

15.5.3 SWOT Analysis of Novo Nordisk

15.5.4 Novo Nordisk Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

#### 15.6 Novartis AG

15.6.1 Company Profile

15.6.2 Main Business and Non-alcoholic Steatohepatitis Drug Information

15.6.3 SWOT Analysis of Novartis AG

15.6.4 Novartis AG Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

#### 15.7 Pfizer Inc.

15.7.1 Company Profile

15.7.2 Main Business and Non-alcoholic Steatohepatitis Drug Information

15.7.3 SWOT Analysis of Pfizer Inc.

15.7.4 Pfizer Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

#### 15.8 Roche Holding AG

15.8.1 Company Profile

15.8.2 Main Business and Non-alcoholic Steatohepatitis Drug Information

15.8.3 SWOT Analysis of Roche Holding AG

15.8.4 Roche Holding AG Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

#### 15.9 Enanta Pharmaceuticals Inc.

15.9.1 Company Profile

15.9.2 Main Business and Non-alcoholic Steatohepatitis Drug Information

15.9.3 SWOT Analysis of Enanta Pharmaceuticals Inc.

15.9.4 Enanta Pharmaceuticals Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

#### 15.10 Ionis Pharmaceuticals Inc.

15.10.1 Company Profile

15.10.2 Main Business and Non-alcoholic Steatohepatitis Drug Information

15.10.3 SWOT Analysis of Ionis Pharmaceuticals Inc.

15.10.4 Ionis Pharmaceuticals Inc. Non-alcoholic Steatohepatitis Drug Revenue, Gross Margin and Market Share (2020-2025)

Please ask for sample pages for full companies list

Tables and Figures

Table Abbreviation and Acronyms	
Table Research Scope of Non-Alcoholic Steatohepatitis Drug Report	
Table Data Sources of Non-Alcoholic Steatohepatitis Drug Report	
Table Major Assumptions of Non-Alcoholic Steatohepatitis Drug Report	
Figure Market Size Estimated Method	
Figure Major Forecasting Factors	
Figure Non-Alcoholic Steatohepatitis Drug Picture	
Table Non-Alcoholic Steatohepatitis Drug Classification	
Table Non-Alcoholic Steatohepatitis Drug Applications	
Table Drivers of Non-Alcoholic Steatohepatitis Drug Market	
Table Restraints of Non-Alcoholic Steatohepatitis Drug Market	
Table Opportunities of Non-Alcoholic Steatohepatitis Drug Market	
Table Threats of Non-Alcoholic Steatohepatitis Drug Market	
Table Covid-19 Impact For Non-Alcoholic Steatohepatitis Drug Market	
Table Raw Materials Suppliers	
Table Different Production Methods of Non-Alcoholic Steatohepatitis Drug	
Table Cost Structure Analysis of Non-Alcoholic Steatohepatitis Drug	
Table Key End Users	
Table Latest News of Non-Alcoholic Steatohepatitis Drug Market	
Table Merger and Acquisition	
Table Planned/Future Project of Non-Alcoholic Steatohepatitis Drug Market	
Table Policy of Non-Alcoholic Steatohepatitis Drug Market	
Table 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size	
Figure 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size and CAGR	
Table 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size by Application	
Table 2020-2025 North America Non-Alcoholic Steatohepatitis Drug Key Players Revenue	
Table 2020-2025 North America Non-Alcoholic Steatohepatitis Drug Key Players Market Share	
Table 2020-2030 North America Non-Alcoholic Steatohepatitis Drug Market Size by Type	
Table 2020-2030 United States Non-Alcoholic Steatohepatitis Drug Market Size	
Table 2020-2030 Canada Non-Alcoholic Steatohepatitis Drug Market Size	
Table 2020-2030 Mexico Non-Alcoholic Steatohepatitis Drug Market Size	
Table 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size	
Figure 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size and CAGR	

Table 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size by Application

Table 2020-2025 South America Non-Alcoholic Steatohepatitis Drug Key Players Revenue

Table 2020-2025 South America Non-Alcoholic Steatohepatitis Drug Key Players Market Share

Table 2020-2030 South America Non-Alcoholic Steatohepatitis Drug Market Size by Type

Table 2020-2030 Brazil Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Argentina Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Chile Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Peru Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size

Figure 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size and CAGR

Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size by Application

Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Key Players Revenue

Table 2020-2025 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Key Players Market Share

Table 2020-2030 Asia & Pacific Non-Alcoholic Steatohepatitis Drug Market Size by Type

Table 2020-2030 China Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 India Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Japan Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 South Korea Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Southeast Asia Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Australia Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size

Figure 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size and CAGR

Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size by Application

Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Drug Key Players Revenue

Table 2020-2025 Europe Non-Alcoholic Steatohepatitis Drug Key Players Market Share

Table 2020-2030 Europe Non-Alcoholic Steatohepatitis Drug Market Size by Type

Table 2020-2030 Germany Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 France Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 United Kingdom Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Italy Non-Alcoholic Steatohepatitis Drug Market Size

Table 2020-2030 Spain Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Belgium Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Netherlands Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Austria Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Poland Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Russia Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size  
Figure 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size and CAGR  
Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size by Application  
Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Drug Key Players Revenue  
Table 2020-2025 MEA Non-Alcoholic Steatohepatitis Drug Key Players Market Share  
Table 2020-2030 MEA Non-Alcoholic Steatohepatitis Drug Market Size by Type  
Table 2020-2030 Egypt Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Israel Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 South Africa Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Gulf Cooperation Council Countries Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2030 Turkey Non-Alcoholic Steatohepatitis Drug Market Size  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size by Region  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size Share by Region  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size by Application  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Share by Application  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Revenue  
Figure 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size and Growth Rate  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Market Share  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Size by Type  
Table 2020-2025 Global Non-Alcoholic Steatohepatitis Drug Market Share by Type  
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size by Region  
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size Share by Region  
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size by Application  
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Share by Application  
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Revenue  
Figure 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size and Growth Rate

Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Key Vendors Market Share  
Table 2025-2030 Global Non-Alcoholic Steatohepatitis Drug Market Size by Type  
Table 2025-2030 Non-Alcoholic Steatohepatitis Drug Global Market Share by Type

## I would like to order

Product name: Non-alcoholic Steatohepatitis Drug Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology

Product link: <https://marketpublishers.com/r/N65FC5A11CFFEN.html>

Price: US\$ 3,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N65FC5A11CFFEN.html>